- Home
- CRDO vs ROIV Comparison
CRDO vs ROIV Comparison
Compare CRDO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDO
- ROIV
- Stock Information
- Founded
- CRDO 2008
- ROIV 2014
- Country
- CRDO Cayman Islands
- ROIV United Kingdom
- Employees
- CRDO N/A
- ROIV N/A
- Industry
- CRDO Semiconductors
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CRDO Technology
- ROIV Health Care
- Exchange
- CRDO Nasdaq
- ROIV Nasdaq
- Market Cap
- CRDO 18.9B
- ROIV 8.6B
- IPO Year
- CRDO 2022
- ROIV N/A
- Fundamental
- Price
- CRDO $136.23
- ROIV $17.10
- Analyst Decision
- CRDO Strong Buy
- ROIV Strong Buy
- Analyst Count
- CRDO 12
- ROIV 8
- Target Price
- CRDO $129.91
- ROIV $19.94
- AVG Volume (30 Days)
- CRDO 6.6M
- ROIV 7.4M
- Earning Date
- CRDO 12-01-2025
- ROIV 11-11-2025
- Dividend Yield
- CRDO N/A
- ROIV N/A
- EPS Growth
- CRDO N/A
- ROIV N/A
- EPS
- CRDO 0.67
- ROIV N/A
- Revenue
- CRDO $600,135,000.00
- ROIV $23,233,000.00
- Revenue This Year
- CRDO $126.91
- ROIV N/A
- Revenue Next Year
- CRDO $28.04
- ROIV $200.91
- P/E Ratio
- CRDO $202.85
- ROIV N/A
- Revenue Growth
- CRDO 175.81
- ROIV N/A
- 52 Week Low
- CRDO $29.09
- ROIV $8.73
- 52 Week High
- CRDO $176.70
- ROIV $17.28
- Technical
- Relative Strength Index (RSI)
- CRDO 45.67
- ROIV 81.16
- Support Level
- CRDO $128.80
- ROIV $15.91
- Resistance Level
- CRDO $151.67
- ROIV $16.39
- Average True Range (ATR)
- CRDO 10.40
- ROIV 0.52
- MACD
- CRDO -2.71
- ROIV 0.02
- Stochastic Oscillator
- CRDO 26.73
- ROIV 92.55
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.